We use a variety of methods including structural and functional neuroimaging, neurocognitive and genetic methods, computational modelling, pharmacological and clinical studies. We are particularly interested in improving prediction of psychotic disorders in young high-risk patients, and in investigating the neurofunctional mechanisms and efficacy of potential innovative treatments such as cannabinoids.